Underwriting of unlisted options completed
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited has completed the underwriting of options, issuing a significant number of Shortfall Shares under an agreement with Forrest Capital Pty Ltd, as reported on page one. This issuance provides additional funding for the company, ensuring a cash runway until late in the following year or early the year after that, also noted on page one. The announcement confirms that all underwritten options have been converted prior to their expiry, which is detailed on page one.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW Alzheimers pivotal trial completes last patient visit
- ACW unlisted options fully underwritten
- ACW FY2026 results and outlook
- ACW Appendix 4E and 2026 annual report
- June 2026 Quarterly activity report & Appendix 4C
Later from Actinogen Medical
- Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
- ACW September 2026 quarterly activity report & Appendix 4C
- ACW pivotal Alzheimers trial database lock - results mid-Nov
- Actinogen receives $10.8m R&D tax incentive rebate from ATO
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical